Evidence map›Paper›PMID 40917514›Full record

ArticleMaterials today. Bio2025

Engineered biomimetic vesicles induce cuproptosis and disrupt efferocytosis for metastatic adenoid cystic carcinoma immunotherapy.

Mingyang Li, Wenjing Dong, Yuhan Cui, Jingwen Li, Chenyu Yang, Dongsheng Zhang, Xiao Fu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. ZIF-8 nanoplatform coordinating ZnInternational journal of pharmaceutics: X · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mingyang LiDepartment of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, 250021, Shandong, China.
Wenjing DongDepartment of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, 250021, Shandong, China.
Yuhan CuiDepartment of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, 250021, Shandong, China.
Jingwen LiDepartment of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, 250021, Shandong, China.
Chenyu YangDepartment of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, 250021, Shandong, China.
Dongsheng ZhangDepartment of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, 250021, Shandong, China.
Xiao FuDepartment of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, 250021, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenoid cystic carcinoma (ACC) is a lethal salivary gland malignant neoplasm. Lung metastasis is the primary cause of mortality in ACC patients while there is no effective treatment available at present. In this study, a precise and biomimetic nanoplatform, CG/MC/U-M, is designed to combine cuproptosis, gas therapy and immunotherapy against metastatic adenoid cystic carcinoma. CG/MC/U-M was derived from ACC cell membranes, encapsulating carbonyl manganese (Mn

Indexed as

Adenoid cystic carcinoma (ACC)CuproptosisEfferocytosisImmunotherapyLung metastasis

Identifiers

PMID40917514
PMCPMC12408398

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.